GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trex Wind Down Inc (OTCPK:TMBRQ) » Definitions » Net Current Asset Value

Trex Wind Down (Trex Wind Down) Net Current Asset Value : $-1.04 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Trex Wind Down Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Trex Wind Down's net current asset value per share for the quarter that ended in Jun. 2023 was $-1.04.

The historical rank and industry rank for Trex Wind Down's Net Current Asset Value or its related term are showing as below:

During the past 3 years, the highest Price-to-Net-Current-Asset-Value Ratio of Trex Wind Down was 28.08. The lowest was 1.09. And the median was 3.01.

TMBRQ's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.96
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Trex Wind Down Net Current Asset Value Historical Data

The historical data trend for Trex Wind Down's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trex Wind Down Net Current Asset Value Chart

Trex Wind Down Annual Data
Trend Dec20 Dec21 Dec22
Net Current Asset Value
12.36 9.81 1.61

Trex Wind Down Quarterly Data
Apr19 Apr20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 2.65 1.61 0.18 -1.04

Competitive Comparison of Trex Wind Down's Net Current Asset Value

For the Biotechnology subindustry, Trex Wind Down's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trex Wind Down's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trex Wind Down's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Trex Wind Down's Price-to-Net-Current-Asset-Value falls into.



Trex Wind Down Net Current Asset Value Calculation

Trex Wind Down's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(9.813-5.041-0-0)/2.96927
=1.61

Trex Wind Down's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2023 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(2.791-5.947-0-0)/3.04743
=-1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trex Wind Down  (OTCPK:TMBRQ) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Trex Wind Down Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Trex Wind Down's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Trex Wind Down (Trex Wind Down) Business Description

Traded in Other Exchanges
N/A
Address
3 Mountain View Road, Suite 100, Warren, NJ, USA, 07059
Timber Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Its investigational therapies have mechanisms of action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles. The company is focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI), and other sclerotic skin diseases. The company's late-stage program is TMB-001., and TMB-003 is the earliest-stage program.
Executives
John Koconis director, officer: Chief Executive Officer C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Alan Mendelsohn officer: Chief Medical Officer C/O TIMBER PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE A26, WOODCLIFF LAKE NJ 07677
Edward J Sitar director 39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Tardimed Sciences Llc 10 percent owner 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Lubor Gaal director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Kimberly Bragg officer: Controller C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Amir Tavakkol officer: Chief Scientific Officer C/O VIAMET PHARMACEUTICALS HOLDINGS LLC, 4505 EMPEROR BLVD., SUITE 300, DURHAM NC 27703
Michael Derby director, officer: Executive Chairman 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Zachary Rome director, officer: Executive VP, COO and Sec. C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Joseph Lucchese officer: Executive VP & CFO C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Stocum director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Linda A Broenniman director 1895 PRESTON WHITE DR, STE 250, RESTON VA 20191
Gianluca Pirozzi director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMITON AVENUE, SUITE 100, CAMPBELL CA 95008
Timber Pharmaceuticals Llc 10 percent owner 50 TICE BOULEVARD, SUITE A26, WOODCLIFF LAKE NJ 07677